Safety and efficacy of a modified XELOX adjuvant regimen for patients with operated stage III colon cancer:a Chinese single-center experience

作     者：Jianhong Peng Weihao Li Rongxin Zhang Junzhong Lin Jinghua Tang Yongshan Wen Zhenhai Lu Xiaojun Wu Zhizhong Pan 

作者机构：Department of Colorectal SurgeryState Key Laboratory of Oncology in South ChinaCollaborative Innovation Center for Cancer MedicineSun Yat-sen University Cancer Center651 Dongfeng Road EastGuangzhouGuangdong 510060P.R.China 

出 版 物：《Cancer Communications》 (癌症通讯（英文）)

年 卷 期：2019年第39卷第1期

页      面：536-547页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：This work was funded by grants from National Natural Science Foundation of China(Grant No.81772595) Sun Yat-sen University Clinical Research 5010 Program(2015024) Sun Yat-sen University Clinical Research 5010 Program(2013013) Guangzhou Science and Technology Plan Projects(Health Medical Collaborative Innovation Program of Guangzhou)(Grant No.201803040019) 

主　　题：Colon cancer Adjuvant chemotherapy Oxaliplatin Capecitabine XELOX Efficacy Safety 

摘      要：Background:A fixed 8-cycle oxaliplatin and capecitabine(XELOX)regimen has been the standard adjuvant therapy for patients with stage III colon ***,completing the full-cycle of oxaliplatin is often associated with severe *** spare patients from the toxic effects,without comprising the required efficacy,we evaluated the safety and efficacy of a modified XELOX(mXELOX)adjuvant chemotherapy regimen with 6 cycles of oxaliplatin and a full cycle of ***:We retrospectively analyzed 330 eligible patients with stage III colon cancer who underwent cura-tive tumor resection followed by mXELOX,standard XELOX or unfinished XELOX adjuvant chemotherapy between December 2007 and April *** prognostic factors were investigated and their disease-free survival(DFS)and overall survival(OS)rates were also determined and compared among the different regimen ***:Compared with the standard XELOX group,the mXELOX group had lower total incidence rates of neuro-toxicity(39.3%vs.76.2%,P0.001),leucopenia(53.6%vs.69.8%,P=0.017)and thrombocytopenia(38.1%vs.56.3%,P=0.011).The standard XELOX and mXELOX adjuvant chemotherapy regimens presented with comparable 3-year DFS rates(86.3%vs.89.2%;P=0.838)and 3-year OS rates(92.7%vs.97.6%;P=0.227).Compared to unfinished XELOX chemotherapy,the oncologic benefits of the mXELOX regimen were greater for patients with T4 tumors(3-year DFS:Hazard ratio[HR],2.184;95%confidence interval[CI],1.051-4.540;P=0.036;3-year OS:HR,4.529;95%CI 1.245-16.479;P=0.022)and for high-risk patients(3-year DFS:HR,1.962;95%CI 0.964-3.993;P=0.044;3-year OS:HR,4.193;95%CI 1.182-14.874;P=0.026).Conclusions:The mXELOX adjuvant chemotherapy presented a comparable survival benefit and lower incidence of toxicity than standard XELOX *** could be an alternative treatment for high-risk patients with operated stage III colon cancer.